文献速递银屑病与炎症性皮肤病

银屑病患者司库奇尤单抗应答的药物遗传学生物标志物:真实临床实践研究

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-12-28

本研究在15家西班牙医院纳入中重度斑块状银屑病患者,分析180个SNP与司库奇尤单抗应答的关联。6个月时67%达到绝对PASI≤3、65%达到PASI≤1;12个月时分别为75%和64%。多变量模型显示4个SNP与6个月绝对PASI≤3相关,联合基因型、体重和生物制剂治疗史的AUC为0.88(95%CI 0.83-0.94),敏感度48.6%、特异度95.7%。

要点

  • rs1801274、rs2431697和rs10484554为6个月未达绝对PASI≤3的风险因素。
  • rs1051738为保护因素。
  • 联合模型AUC 0.88,特异度95.7%,敏感度48.6%。

核心结论

  • 已鉴定出一系列与司库奇尤单抗应答相关的多态性,能够预测斑块状银屑病患者对该药的潜在应答或不答。

研究设计与样本

  • 研究在15家西班牙医院招募中重度斑块状银屑病患者,分析180个SNP,采用定制Taqman阵列进行基因分型并构建多变量逻辑回归模型。
  • 6个月时纳入173例患者,12个月时纳入162例患者。
  • 疗效以6个月和12个月时绝对PASI≤3和≤1评估。

主要发现

  • 6个月时67%达到绝对PASI≤3,65%达到PASI≤1;12个月时75%达到绝对PASI≤3,64%达到PASI≤1。
  • 多变量分析显示不同SNP组合与司库奇尤单抗应答相关,其中6个月绝对PASI≤3模型敏感度和特异度最佳。
  • rs1801274(FCGR2A)、rs2431697(miR-146a)和rs10484554(HLCw6)为6个月未达绝对PASI≤3的风险因素,rs1051738(PDE4A)为保护因素。
  • 包含上述基因型、患者体重和生物制剂治疗史的AUC为0.88(95%CI 0.83-0.94),区分两种表型的敏感度48.6%、特异度95.7%。

关键数值与推荐

  • 6个月时67%达到绝对PASI≤3,65%达到PASI≤1;12个月时75%达到绝对PASI≤3,64%达到PASI≤1。
  • 联合基因型、体重和生物制剂治疗史的模型AUC为0.88(95%CI 0.83-0.94),敏感度48.6%、特异度95.7%。

临床怎么用

  • 这些多态性有望用于预测斑块状银屑病患者对司库奇尤单抗的潜在应答或不答,辅助治疗分配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation. OBJECTIVE: To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting. METHODS: We studied 180 SNPs in patients with moderate-to-severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by absolute PASI ≤3 and ≤1 at 6 and 12 months. Individuals were genotyped using a custom Taqman array. Multiple logistic regression models were generated. Sensitivity, specificity and area under the curve (AUC) were analysed. RESULTS: A total of 173 patients were studied at 6 months, (67% achieved absolute PASI ≤ 3 and 65% PASI ≤ 1) and 162 at 12 months (75% achieved absolute PASI ≤ 3 and 64% PASI ≤ 1). Multivariable analysis showed the association of different sets of SNPs with the response to secukinumab. The model of absolute PASI≤3 at 6 months showed best values of sensitivity and specificity. Four SNPs were associated with the capability of achieving absolute PASI ≤ 3 at 6 months. rs1801274 (FCGR2A), rs2431697 (miR-146a) and rs10484554 (HLCw6) were identified as risk factors for failure to achieve absolute PASI≤3, while rs1051738 (PDE4A) was protective. AUC including these genotypes, weight of patients and history of biological therapy was 0.88 (95% CI 0.83-0.94), with a sensitivity of 48.6% and specificity of 95.7% to discriminate between both phenotypes. CONCLUSION: We have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non-response to this drug in patients with plaque psoriasis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Muñoz-Aceituno E, Butrón-Bris B, Ovejero-Benito MC, et al. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice. J Eur Acad Dermatol Venereol. 2023. PMID: 38153843. doi:10.1111/jdv.19782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。